MVM Life Science Partners
Partner with best-in-class management teams to bring innovative healthcare products to market that address significant unmet needs in large addressable markets, with clearly differentiated technology and durable competitive protection.
Check Size$20M – $100M
StagesSeries B, Series C, Series D, Growth
LocationUS
Data quality88verified
Investment thesis
Partner with best-in-class management teams to bring innovative healthcare products to market that address significant unmet needs in large addressable markets, with clearly differentiated technology and durable competitive protection.
90 confidence · stated by fund
Series BSeries CSeries DGrowthMedical DevicesDiagnosticsPharmaceuticalsDigital HealthHealth ITLife Science ToolsContract ResearchContract Manufacturing
Partners
NA
Neil Akhurst
EB
Eric Bednarski
TC
Thomas Casdagli
HH
Hugo Harrod
What sets MVM Life Science Partners apart
- 28 years of investing history since 1997 with 150+ collective years partner experience
- 41 documented successful exits including IPOs and strategic M&A
- Deep healthcare domain expertise with concentrated portfolio approach
- Focus on companies with regulatory moats and clear exit pathways
Recent investments
Neurent Medical, Proverum, Avanzanite
Investment profile
- Stages
- Series B, Series C, Series D, Growth
- Sectors
- Medical Devices, Diagnostics, Pharmaceuticals, Digital Health, Health IT, Life Science Tools, Contract Research, Contract Manufacturing
- Cold inbound
- Warm intro preferred
Frequently asked questions
- What does MVM Life Science Partners invest in?
- MVM Life Science Partners is a series b, series c, series d, growth stage Medical Devices, Diagnostics, Pharmaceuticals, Digital Health, Health IT, Life Science Tools, Contract Research, Contract Manufacturing investor, typically writing $20M – $100M checks, primarily investing in US. Their thesis: Partner with best-in-class management teams to bring innovative healthcare products to market that address significant unmet needs in large addressable markets, with clearly differentiated technology and durable competitive protection.
- What check size does MVM Life Science Partners write?
- MVM Life Science Partners typically writes $20M – $100M checks at the Series B, Series C, Series D, Growth stage in Medical Devices, Diagnostics, Pharmaceuticals, Digital Health, Health IT, Life Science Tools, Contract Research, Contract Manufacturing.
- Is MVM Life Science Partners actively deploying capital?
- MVM Life Science Partners is actively deploying capital. What we observed: Active portfolio with recent investments through Feb 2026 (Neurent Medical, Proverum, Avanzanite) and ongoing news of portfolio company milestones and exits.
- What makes MVM Life Science Partners different from other funds?
- MVM Life Science Partners stands out on 4 points: 28 years of investing history since 1997 with 150+ collective years partner experience; 41 documented successful exits including IPOs and strategic M&A; Deep healthcare domain expertise with concentrated portfolio approach; Focus on companies with regulatory moats and clear exit pathways.
- What has MVM Life Science Partners invested in recently?
- Recent investments DryPowder has tracked from MVM Life Science Partners include Neurent Medical, Proverum, Avanzanite.
- How do I reach out to MVM Life Science Partners?
- MVM Life Science Partners doesn't generally take cold inbound — a warm introduction from a founder or investor they already know is the reliable path in. Use DryPowder's AI fund matching to see how your startup aligns with MVM Life Science Partners's thesis and focus areas (Medical Devices, Diagnostics, Pharmaceuticals, Digital Health, Health IT, Life Science Tools, Contract Research, Contract Manufacturing) — it returns a fit score and specific talking points for your outreach.